VEGF inhibitors work by binding to VEGF or its receptors on the surface of endothelial cells, thereby preventing VEGF from activating its signaling pathways. This leads to a reduction in the formation of new blood vessels, restricting the tumor's ability to grow and spread. Some common VEGF inhibitors include Bevacizumab, Sorafenib, and Sunitinib.
